每经AI快讯,中信建投研报表示,23年底以来海外投融资逐渐恢复,下游需求维持向好,国内投融资底部趋稳,下游需求仍有待恢复。受益于国内CXO产业链的全面以及竞争力的领先,行业受地缘政治影响目前较为有限。国内临床前及临床CRO价格趋稳,经营趋势有望逐渐向上。CDMO企业商业化需求稳定,大订单影响24Q4开始已经消除。近年来在ADC、多肽药物快速发展下,相关CXO需求迅速增加,小核酸、CGT等细分领域也...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.